Pharmaceutical - Johnson & Johnson

Filter

Current filters:

Johnson & Johnson

Popular Filters

226 to 250 of 260 results

Janssen drops deal with Orexo for OX-CLI/OX-ESI

01-02-2012

US health care major Johnson & Johnson INYSE: JNJ) subsidiary Janssen has decided to end research collaboration…

FinancialJanssenJohnson & JohnsonLicensingOrexo ABPharmaceuticalRespiratory and Pulmonary

Johnson & Johnson beats forecast despite profits slump

25-01-2012

US health care giant Johnson & Johnson (NYSE: JNJ) has announced sales of $16.3 billion for the fourth…

FinancialJohnson & JohnsonPharmaceutical

Germany’s IQWiG sees added benefits for Incivo

24-01-2012

In an early benefit assessment pursuant to Germany’s Act on the Reform of the Market for Medicinal…

Anti-viralsEuropeIncivekIncivoJanssenJohnson & JohnsonPharmaceuticalPricingRegulationVertex

Merck & Co and Johnson & Johnson settlements

20-01-2012

US drug giant Merck & Co (NYSE: MRK) revealed yesterday that it has entered into an agreement to resolve…

FinancialJohnson & JohnsonLegalMerck & CoNeurologicalNorth AmericaPharmaceuticalRisperdalVioxx

Zytiga overtaking Provenge in MCRPC

17-01-2012

Despite no current approval of Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Zytiga (abiraterone)…

BiotechnologyDendreonJanssenJevtanaJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalProvengeSanofiZytiga

Two UK product launches

16-01-2012

Danish drugmaker Lundbeck (LUND: DC) announced yesterday that Sycrest (asenapine) is being launched in…

Anti-viralsEuropeIntelenceJanssenJohnson & JohnsonLundbeckMarkets & MarketingNeurologicalPharmaceuticalSaphrisSycrest

Another mega deal for FORMA Therapeutics

11-01-2012

Hot on the heels of its up to $815 million oncology-related deal with Boehringer Ingelheim (The Pharma…

BiotechnologyFORMA TherapeuticsJanssen BiotechJohnson & JohnsonLicensingOncologyPharmaceuticalResearch

Johnson & Johnson stops Doribax trial; reportedly agrees Risperdal settlement

09-01-2012

The US Food and Drug Administration says that a recent clinical trial with Doribax (doripenem) being…

DoribaxFinancialJanssenJohnson & JohnsonLegalNeurologicalNorth AmericaPharmaceuticalResearchRespiratory and PulmonaryRisperdal

J&J’s Zytiga offers considerable added benefit in certain patients

09-01-2012

US health care giant Johnson & Johnson’s Zytiga (abiraterone) was approved in Europe last fall for…

Johnson & JohnsonOncologyPharmaceuticalRegulationResearchZytiga

Phylogica signs deal with Johnson & Johnson unit

04-01-2012

Australian peptide drug discovery company Phylogica (ASX: PYC) has entered into a collaboration and option…

BiotechnologyFinancialJanssen BiotechJohnson & JohnsonLicensingPharmaceuticalPhylogica

Janssen files Xarelto sNDA for ACS; FDA to review Amgen’s Xgeva for CRPC

30-12-2011

US health care giant Johnson & Johnson’s (NYSE: JNJ) Janssen Research & Development, has submitted…

AmgenBayerBiotechnologyCardio-vascularJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRegulationXareltoXgeva

Metamark could earn over $365 million from Janssen deal

20-12-2011

Privately-held US firm Metamark Genetics has entered into a research, collaboration and license agreement…

Janssen BiotechJohnson & JohnsonLicensingMetamark GeneticsOncologyPharmaceuticalResearch

Outlook for VTE treatment and prophylaxis market

14-12-2011

Driven primarily by the launches and strong uptake of oral anticoagulants, the combined markets for drugs…

BayerBristol-Myers SquibbCardio-vascularEliquisJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

FDA panel mixed on Ortho Evra

12-12-2011

The majority of members of the US Food and Drug Administration’s Reproductive Health Drugs Advisory…

Johnson & JohnsonNorth AmericaOrtho EvraPharmaceuticalRegulationReproductiveWomen's Health

J&J to pay nearly $1 billion for cancer drug candidate

09-12-2011

US health care giant Johnson & Johnson (NYSE: JNJ), through its subsidiary Janssen Biotech, has executed…

Janssen BiotechJohnson & JohnsonLicensingOncologyPharmaceuticalPharmacyclics

New start-up TopiVert gets $12.5 million funding

06-12-2011

UK investment group Imperial Innovations (AIM: IVO) and SV Life Sciences have committed to invest £8…

FinancialInflammatory diseasesJohnson & JohnsonPharmaceuticalResearchRespiVertTopiVert

Bristol-Myers links with Tibotec for Ph II combination study in hepatitis C patients

05-12-2011

US drug major Bristol-Myers Squibb (NYSE: BMY) has entered into a clinical collaboration agreement with…

Anti-viralsBristol-Myers SquibbdaclatasvirJohnson & JohnsonMedivirPharmaceuticalResearchTibotec

Gilead and Johnson & Johnson get EU backing for HIV drugs Eviplera and Edurant, respectively

29-11-2011

In the first of two pieces of good news for HIV/AIDS drug developers, US biotech firm Gilead Sciences…

Anti-viralsEdurantEuropeEvipleraGilead SciencesJanssen-CilagJohnson & JohnsonPharmaceuticalRegulationTibotec

Gilead in another licensing deal with J&J unit for combo HIV/AIDS treatment

16-11-2011

US biotech firm Gilead Sciences (Nasdaq: GILD) has entered into a license agreement with Tibotec Pharmaceuticals,…

Anti-viralsBiotechnologycobicistatEmtrivaGilead SciencesJohnson & JohnsonLicensingPharmaceuticalPrezistaResearchTibotec

Despite generics for two key drugs, neuropathic pain market will grow to $8.4 billion in 2020

13-11-2011

The neuropathic pain drug market will experience modest growth over the next decade, increasing from…

Astellas PharmaEli LillyJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceutical

Affymax and Janssen Biotech enter $13 million peginesatide patent settlement

11-11-2011

US biotech firm Affymax (Nasdaq: AFFY) says it has reached a global settlement agreement with Janssen…

AffymaxBiotechnologyJanssen PharmaceuticaJohnson & JohnsonOncologyPatentspeginesatidePharmaceuticalTakeda Pharmaceuticals

Emerging therapies will drive prostate cancer drug market to $10.1 billion in 2020

08-11-2011

Driven by the launches of several promising emerging therapies, the prostate cancer drug market will…

Astellas PharmaBiotechnologyGlobalJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalZytiga

US FDA clears Bayer/Johnson & Johnson’s Xarelto for stroke risk reduction in AF patients

07-11-2011

In what was much-awaited good news for German drug major Bayer (BAY: DE), its US subsidiary announced…

BayerCardio-vascularJanssen PharmaceuticaJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

226 to 250 of 260 results

Back to top